Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose cyclophosphamide plus TKI, PD-1 inhibitor and TACE in unresectable hepatocellular carcinoma
ChiCTR2100053364Phase 2Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in hepatocellular carcinoma (HCC), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Objective response rate. Started Nov 2021; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100053364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053364.